You are leaving Lundbeck.com/US
You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit.
Pipeline
Therapies in development
Our research and development teams aim to target the underlying mechanisms of brain disease. We move together towards a singular goal to deliver novel therapies that redefine the standard of care for patients and address the areas in brain disease where we see the greatest need.
Hormonal / neuropeptide signaling
| Project | Area | Phase 1 | Phase 2 | Phase 3 | Filing | ||||
|---|---|---|---|---|---|---|---|---|---|
| Eptinezumab (anti-CGRP mAb)¹ | Migraine prevention² | Filing | |||||||
|
Mode of action Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache. |
|||||||||
| Lu AG09222 (anti-PACAP mAb)³ | Migraine prevention | 2 | |||||||
|
Mode of action Lu AG09222 is an investigational monoclonal antibody designed to bind and inhibit signaling mediated by pituitary adenylate cyclase-activating polypeptide (PACAP); a neuropeptide that is implicated in migraine pathophysiology. |
|||||||||
| Lu AG13909 (anti-ACTH mAb)⁴ | Neurohormonal dysfunctions | 1 | |||||||
Circuitry / neuronal biology
| Project | Area | Phase 1 | Phase 2 | Phase 3 | Filing | ||||
|---|---|---|---|---|---|---|---|---|---|
| Brexpiprazole⁵ | PTSD⁶ | Filing | |||||||
|
Mode of action Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation. *Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc. |
|||||||||
| Lu AF28996 (D1-D2 agonist)⁷ | Parkinson's disease | 1 | |||||||
|
Mode of action Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients. |
|||||||||
| MAGLi program⁸ | Neurology | 1 | |||||||
| Bexicaserin (5HT2C agonist) | Developmental and epileptic encephalopathies | 3 | |||||||
Protein aggregation, folding and clearance
| Project | Area | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|---|
| Amlenetug (anti α-synuclein mAb) | Synucleinopathies (Multiple System Atrophy) | 3 |
Neuroinflammation / Neuroimmunology
| Project | Area | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|---|
| Lu AG22515 (CD40L blocker)⁹ | Neurology | 1 |
More from Lundbeck
Research and Development
R&D of new and improved treatments is at the core of what we do.
Partnering
Partnerships are a key pillar in our strategy to become leaders in brain health.